Moreover, the efficacy of many chemotherapeutic drugs, particularly those that cause DNA damage (e.g., etoposide, cisplatin), depends upon intact TP53/TRP53 functionality, consequently meaning that mutant TP53 cancers often respond poorly to cancer therapy [8]. This evidence concerns the gene TP53 and cancer.